OTC · Biotechnology

BioInvent International AB (publ) (BOVNF) Stock

$3.29 +0.00% OTC: BOVNF Healthcare

BioInvent International AB (publ) is a clinical-stage biotechnology company primarily focused on identifying, exploring, and engineering immunomodulatory antibodies to combat various forms of cancer. The company's activities extend globally, reaching markets in Sweden, across Europe, the United States, Japan, and other international regions.

Valuation

MetricValue
Price$3.29
Market Cap$216.40M
P/E Ratio-4.47
P/B Ratio3.41
P/S Ratio6.87
EPS (TTM)$-5.07
52-Week High$4.70
52-Week Low$3.29
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-53.88%
ROA-62.71%
ROCE-79.77%
Gross Margin98.48%
Operating Margin-161.05%
Net Margin-153.98%
Debt/Equity0.01
Current Ratio5.32

Annual Financials (USD)

Metric20212022202320242025
Revenue$19.0M$326.0M$71.0M$45.0M$226.0M
Operating Profit$-278.0M$-51.0M$-370.0M$-471.0M$-351.0M
Net Profit$-279.0M$-34.0M$-330.0M$-429.0M$-332.0M
EPS$-5.15$-0.55$-5.02$-6.53$-5.07
Op Margin-1436.0%-15.6%-517.7%-1054.2%-155.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.4B$1.7B$1.4B$989.0M$670.0M
Total Liabilities$80.0M$106.0M$90.0M$103.0M$113.0M
Cash$911.0M$515.0M$260.0M$435.0M$355.0M
Borrowings$28.0M$27.0M$23.0M$17.0M$10.0M

Latest News

BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models ACCESS Newswire · Jul 28, 2026 BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026 ACCESS Newswire · Jul 17, 2026 BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026) ACCESS Newswire · Jun 11, 2026 BioInvent's TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026) ACCESS Newswire · Jun 11, 2026 Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight GlobeNewswire · Jun 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-246.0M$-41.0M$-342.0M$-380.0M$-247.0M
Investing Cash Flow$-935.0M$-1.3B$46.0M$554.0M$172.0M
Financing Cash Flow$-6.0M$-6.0M$-8.0M$-8.0M$-9.0M
Net Cash Flow$181.0M$-396.0M$-255.0M$175.0M$-6.0M
Free Cash Flow$-259.0M$-54.0M$-355.0M$-391.0M$-254.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.24
EV / EBITDA-3.51
FCF Yield-17.75%
Quick Ratio5.20
Interest Coverage0.00
Return 1Y0.00%
Return 3Y-30.03%
Return 5Y—

Ownership

Insiders Held10.17%
Institutions Held57.84%
Institutions Float Held64.39%
Institutional HolderSharesReport Date
DFA INVESTMENT DIMENSIONS GROUP INC-World ex U.S. Core Eqy. PORT.33,9782026-04-30
Dimensional ETF Trust-Dimensional International Core Equity 2 ETF19,4932026-04-30
DFA INVESTMENT TRUST CO-The Continental Small Company Series11,1402026-04-30
Dimensional ETF Trust-Dimensional World ex U.S. Core Equity 2 ETF15,9622026-04-30
Brighthouse Fd.s TRT II-Brighthouse/Dimensional Intl Small Company POR5,0082026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVCTFAvacta Group Plc $0.94 +3.71% -7.36 $440.30M 0.00%
CLVLYClinuvel Pharmaceuticals Limited $6.83 -2.57% 13.94 $344.42M 0.44%
CYDYCytoDyn Inc. $0.19 +0.00% -5.94 $260.25M 0.00%
GSGTFGenSight Biologics S.A. $0.09 +0.00% -1.04 $14.67M 0.00%
HLOSFHealios K.K. $1.80 +0.00% -9.76 $243.00M 0.00%

About BioInvent International AB (publ)

BioInvent International AB (publ) is a clinical-stage biotechnology company primarily focused on identifying, exploring, and engineering immunomodulatory antibodies to combat various forms of cancer. The company's activities extend globally, reaching markets in Sweden, across Europe, the United States, Japan, and other international regions. Its leading investigational compound is BI-1206, which is being developed to address both non-Hodgkin lymphoma and a range of solid tumors. Beyond this flagship program, BioInvent is advancing a diverse pipeline of therapeutic candidates. These include agents designed to target tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a vital role in regulating the immune system. The company's portfolio also features BT-001 for solid tumor indications, as well as BI-1808 and BI-1910 – both anti-TNFR2 antibodies specifically intended for the treatment of solid tumors and cutaneous T-cell lymphoma. To further its development initiatives, BioInvent has established several key collaborations. It maintains a strategic alliance with Pfizer Inc. for the development of antibodies targeting tumor-associated myeloid cells. The company also collaborates with Transgene to jointly create innovative multi-functional oncolytic viruses aimed at solid tumors. Additionally, a collaboration and supply agreement with Merck facilitates the clinical advancement of BI-1808. Founded in 1996, BioInvent International AB (publ) maintains its headquarters in Lund, Sweden.

BioInvent International AB (publ) is headquartered in SE.

BioInvent International AB (publ) (BOVNF) stock trades at $3.29 with a market capitalization of $216.40M. The stock is valued at a price-to-earnings (P/E) ratio of -4.47, price-to-book of 3.41, price-to-sales of 6.87. Over the past 52 weeks the stock has ranged between $3.29 and $4.70, and currently trades 30.0% below its 52-week high.

On profitability, BioInvent International AB (publ) generates a return on equity (ROE) of -53.88%, return on capital employed of -79.77%, an operating margin of -161.05%, a net profit margin of -153.98%.

Official website: www.bioinvent.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides